Nurul is the Head of Corporate and Research Development at Sengenics Corporation Pte Ltd, a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. Sengenics currently has partnerships with 9 out of the top 20 pharma to co-develop companion diagnostic tests for autoimmune and cancer immunotherapy drugs. Her previous experience in managing KREX operations has enabled her to take on her current role which focuses on accelerating KREX’s R&D pipeline towards FDA approval and commercialisation.
Clinical & Research Tools Showcase:
Sengenics is a functional proteomics company that leverages its patented KREX technology for stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those exhibiting irAEs. KREX can also be used to identify autoantibody biomarkers for early diagnosis of cancer, autoimmune or neurodegenerative conditions.
Realising The Potential of Precision Medicine For Autoimmune And Cancer Drugs Using Sengenics' KREX Technology
Leveraging the Sengenics KREX™ technology, we have developed a fully quantitative protein array platform which enables the simultaneous screening of thousands of functional proteins, making it an ideal platform for the identification of autoantibody biomarkers in the development of in vitro diagnostic tests. This presentation will cover the key applications of our KREX™ technology and array derivatives towards enhancing precision medicine which include patient stratification, predicting treatment responses and biomarker discovery for early diagnosis of cancer and autoimmune diseases.
The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.